ClinicalTrials.gg
CompletedNCT04135898Updated Dec 29, 2023

A Study Comparing SIBP-04 and Bevacizumab in Healthy Male Subjects

A Phase 1 interventional study of SIBP-04 and Bevacizumab in Healthy Male, sponsored by Shanghai Institute Of Biological Products. Completed at 1 site in China. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-29.

Sponsored by Shanghai Institute Of Biological Products (part of Sinopharm) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
88
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

This is a randomised, double-blind, positive drug parallel controlled clinical trial in China. In the trial, it is planned to enroll 88 subjects, randomized to two treatment groups in a ratio of 1:1 to receive the test drug and the positive control.

02

Conditions studied

  • Healthy Male
03

In context

Lead sponsor

Shanghai Institute Of Biological Products is the lead sponsor of 34 studies on the registry; 14 are open to participants now.

First submitted after Shanghai Institute Of Biological Products became part of Sinopharm.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects who are able and willing to give written .
  2. 18-45 years old, male.
  3. (BMI): 18-26 kg/m2 (including 18 kg/m2 and 26 kg/m2), and weighing between 50-80 kg (including 50 kg and 80 kg).
  4. Subjects determined healthy by Vital signs, physical examination, laboratory tests (blood routine, blood biochemistry, coagulation function, urine routine, fecal occult blood, etc.), 12-lead , chest X-ray, abdominal ultrasound, urinary ultrasound, without any abnormality judged by the investigator.
  5. Subjects who are willing to comply with the restrictions from signing of the informed consent form until 6 months after the infusion of the test drug.
  6. Subjects who can participate in the visit on time and complete the visit.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with the following diseases, including but not limited to: nervous system, cardiovascular system, blood and lymphatic system, immune system, digestive system, respiratory system, metabolism and bone diseases.
  2. History of digestive tract perforation or digestive tract disease.
  3. Subjects who are allergic to Avastin® and its ingredients.
  4. History of diseases or allergic diseases.
  5. History of proteinuria (urine routine examination, urinary protein 2+and above) or proteinuria judged by the investigator.
  6. Any inherited predisposition to bleeding or to thrombosis or history of non traumatic hemorrhage (i.e., requiring medical intervention), thromboembolic event or any condition which may increase bleeding risk including clotting disorders, thrombocytopenia ( count \< 125000/µL) or an (INR) higher than 1.5.
  7. Subjects who did strenuous exercise 96 hours before the test, or participate in intense physical activity within 30 days after the scheduled dose, including physical contact or impact sports;
  8. Subject with a family history of cancer or a malignant tumor within the past 5 years.
  9. Abnormal with clinical significance judged by the Investigator.
  10. Subjects with relevant family history of hypertension or abnormal blood pressure at screening or admission to the study center (Day 1): (Systolic blood pressure ≤ 90mmHg or ≥ 140mmHg, or / and diastolic blood pressure ≤ 60mmHg or ≥ 90mmHg), heart rate ≤ 50bpm or ≥ 100bpm.
  11. Subjects who have acute or chronic infectious diseases and have clinical significance during the screening and admission studies, or antibody (HCV-Ab), antibody (HIV-Ab), surface antigen (HBsAg), syphilis test positive during the screening.
  12. History of prior exposure to bevacizumab or any anti VEGF monoclonal antibodies or proteins.
  13. within 3 months prior to study drug administration, or prior exposure to any other monoclonal antibody within 9 months.
  14. Intake of prescribed or over the counter drugs within 5 half-life of the drug or 2 weeks prior to the use of the test drug, or intake of herbal drugs or dietary supplements within 28 days prior to randomization.
  15. Use of any investigational drug in any clinical study within the 3 months prior to Sign .
  16. Blood loss or blood donation (including blood components donation) ≥ 400 mL or blood transfusion within 3 months before study drug administration.
  17. Unhealed wound ulcers or fractures, or major surgery within 2 months prior to randomization or expected major surgery during the study period or 2 months after the end of the study.
  18. Plan to receive oral or dental surgery during the study period.
  19. History of alcohol abuse or a positive alcohol breath test before study drug administration.
  20. History of drug abuse, or have positive drug screening results.
  21. Subjects who have more than 5 cigarettes per day within 3 months before enrollment.
  22. Others that are not in compliance with the enrollment judged by the investigator.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
88 participants (actual)

Study arms

  • Experimental
    SIBP-04

    Drug: SIBP-04

  • Active comparator
    Bevacizumab

    Drug: Bevacizumab

Interventions

06

What researchers measure

Primary outcomes

  1. AUC0-t

    Area under the concentration time curve of the analyte in serum over the time interval from 0 to the last measurable concentration at time "t"

    Time frame: From 0 to day 71

Secondary outcomes

  1. Cmax

    Maximum measured concentration of the analyte in serum

    Time frame: From 0 to day 71

  2. AUCinf

    Area under the concentration time curve of the analyte in serum over the time interval from 0 to extrapolated to infinite time

    Time frame: From 0 to day 71

  3. Tmax

    Time from dosing to maximum measured concentration

    Time frame: From 0 to day 71

  4. t1/2

    Terminal half life of the analyte in serum

    Time frame: From 0 to day 71

  5. λz

    Terminal elimination rate constant

    Time frame: From 0 to day 71

  6. CL

    Total clearance of the analyte in serum following IV infusion

    Time frame: From 0 to day 71

  7. Vd

    Volume of distribution during the terminal phase λz following an intravascular dose

    Time frame: From 0 to day 71

  8. Immunogenicity

    Incidence of anti drug antibodies (ADAs) and neutralizing anti drug antibodies(NAb)

    Time frame: From 0 to day 71

07

Study locations

1 site
  • the First Affiliated Hospital of Bengbu Medical College
    Bengbu, Anhui, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2019 to primary completion in Mar 2020, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2019
First posted
Oct 23, 2019
StartActual
Oct 23, 2019
Primary completionActual
Mar 16, 2020
CompletionActual
Mar 16, 2020
Last update
Dec 29, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 29, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04135898
Responsible party
Sponsor
First posted
Oct 23, 2019
Start date
Oct 23, 2019
Primary completion
Mar 16, 2020
Completion
Mar 16, 2020
Last update
Dec 29, 2023

Study contacts

Shanghai Institute Of Biological Products Co., Ltd
study director · SINOPHARM
The First Affiliated Hospital
principal investigator · Bengbu Medical College

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bevacizumab

Start the discussion